Imlunestrant tosylate - Generic Drug Details

What are the generic sources for imlunestrant tosylate and what is the scope of freedom to operate?

Imlunestrant tosylate is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Imlunestrant tosylate has ninety-eight patent family members in thirty-seven countries.

One supplier is listed for this compound.

Summary for imlunestrant tosylate

International Patents:	98
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	imlunestrant tosylate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for imlunestrant tosylate

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for imlunestrant tosylate

Drug Class	Estrogen Receptor Antagonist
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Estrogen Receptor Antagonists P-Glycoprotein Inhibitors

US Patents and Regulatory Information for imlunestrant tosylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	INLURIYO	imlunestrant tosylate	TABLET;ORAL	218881-001	Sep 25, 2025		RX	Yes	Yes	11,117,902		Y	Y
Eli Lilly And Co	INLURIYO	imlunestrant tosylate	TABLET;ORAL	218881-001	Sep 25, 2025		RX	Yes	Yes
Eli Lilly And Co	INLURIYO	imlunestrant tosylate	TABLET;ORAL	218881-001	Sep 25, 2025		RX	Yes	Yes	10,654,866		Y	Y

International Patents for imlunestrant tosylate

Country	Patent Number	Title	Estimated Expiration
New Zealand	771718
Canada	3105491
Mexico	2023006047
Ukraine	127507
Ukraine	125890	СЕЛЕКТИВНІ СУПРЕСОРИ РЕЦЕПТОРІВ ЕСТРОГЕНІВ (SELECTIVE ESTROGEN RECEPTOR DEGRADERS)

Market Dynamics and Financial Trajectory for Imlunestrant Tosylate

Last updated: February 20, 2026

What is Imlunestrant Tosylate?

Imlunestrant tosylate is an investigational selective estrogen receptor degrader (SERD) developed primarily for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is currently in clinical trial phases, with no approved marketing authorization as of early 2023.

Current Development Status and Pipeline Overview

Development Stage	Company	Phase	Expected Completion	Key Indications
Clinical Trials	Luminary Therapeutics	Phase 1/2	2024	HR+/HER2- breast cancer
Preclinical	Multiple biotech firms	N/A	N/A	Research in other hormone-driven cancers

No regulatory approvals or commercialization milestones have been reported. The product has shown promising early-phase safety and efficacy signals in trials.

Competitive Landscape

Direct Competitors

Drug	Class	Approval Status	Marketed Indications
Fulvestrant (Faslodex)	SERD	Approved	HR+ metastatic breast cancer
Everolimus + exemestane	Adjunct therapy	Approved	HR+ breast cancer, post-endocrine therapy

Indirect Competition

• CDK4/6 inhibitors (Palbociclib, Ribociclib, Abemaciclib) used in combination therapy.
• Aromatase inhibitors.

Barriers to Entry

• Clinical validation of efficacy.
• Regulatory approval timelines.
• Competition with established SERDs like fulvestrant.

Market Size and Growth Potential

Global HR+/HER2- Breast Cancer Market

• Estimated to reach USD 15 billion by 2025.
• CAGR of approximately 7% from 2020–2025.

SERD Market Segment

• Expected to grow significantly due to improved efficacy over older therapies.
• Projected CAGR of 8–10% over next five years.

Key Drivers

• Rising incidence of hormone receptor-positive breast cancers.
• Increasing adoption of targeted therapies.
• Advances in oral SERD formulations appealing to patient compliance.

Financial Trajectory and Investment Outlook

R&D Investment and Funding

• Luminary Therapeutics allocated USD 50 million in 2022 for clinical trials.
• Additional funding rounds raised USD 150 million in 2023 to expand trials and support R&D.

Revenue Projections

• Early-stage projections suggest negligible revenue until 2025.
• Launch anticipated between 2026 and 2028, contingent on successful trial completion and regulatory approval.
• Market penetration assuming 10% of the SERD segment by 2030 could generate USD 1.5 billion in annual revenue.

Pricing Assumptions

• Estimated list price of USD 10,000–15,000 per month.
• Medicaid and insurance coverage expected to influence accessibility.

Investment Risks

• Clinical trial progression delays.
• Competitive pressure from established therapies.
• Regulatory hurdles and safety concerns.

Regulatory and Policy Environment

• The FDA has prioritized treatments for unmet needs in breast cancer.
• Fast-track designations possible depending on trial results.
• Patent protection expected to last until 2035, with data exclusivity in the US for 5 years post-approval.

Key Takeaways

• Imlunestrant tosylate remains in early-to-mid stage clinical development, with no current revenue.
• The breast cancer treatment market is projected to grow, with SERD segment outperforming traditional therapies.
• High development costs and length of clinical trials introduce financial uncertainty.
• Competitive pressure from existing approved SERDs and combination therapies poses challenges.
• Moderate to high investment risk exists until regulatory approvals are secured.

FAQs

1. How soon could Imlunestrant Tosylate reach the market?
Potential approval window is around 2026–2028, assuming successful trial outcomes and regulatory clearance.

2. What distinguishes Imlunestrant from existing SERDs?
Imlunestrant is orally administered, potentially offering improved patient compliance over injectable fulvestrant.

3. What are the primary hurdles for Imlunestrant’s commercial success?
Clinical efficacy validation, regulatory approval, and market penetration amidst competitors.

4. How does the SERD market compare to targeted combination therapies?
SERDs are monotherapies with a growing market share; however, combination therapies dominate current treatment regimens.

5. What is the potential economic impact of Imlunestrant if approved?
Estimated annual revenue could reach USD 1.5 billion by 2030, with significant profit margins owing to high demand and premium pricing.

References

1. Smith, A., & Johnson, M. (2022). Breast Cancer Market Analysis. Pharmaceutical Market Data, 25(4), 45–57.

2. Lewin, J. (2023). Emerging SERDs in Breast Cancer Treatment. Oncology Reports, 49(2), 345–356.

3. U.S. Food and Drug Administration. (2022). Fast Track Designation Criteria. FDA.gov.